“Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation” (2019) Mediterranean Journal of Hematology and Infectious Diseases, 11(1), p. e2019057. doi:10.4084/mjhid.2019.057.